Episode Summary

The highly informed and deeply compassionate Amy Emerson joins Jef Szi and the How Humans Work Podcast for a remarkable conversation about the evolving landscape of psychedelics.

With her extensive involvement and leadership in the Multidisciplinary Association of Psychedelic Studies (MAPS)* and their multi-year effort to get MDMA approved by FDA as a therapeutic medicine for PTSD. There are few better than Amy who can speak to the state of psychedelics for medical use in society.

Not only does Amy share her honest appraisal about FDA drug approval process and members of congress on the Hill, she gives us the little known and fascinating history of MDMA. Some highlights are Sasha and Ann Shulgin’s groundbreaking contributions, the reputational damage MDMA suffered in the 90’s, the long-game efforts of Rick Doblin and others, the powerful way MDMA works on the brain, and the remarkable promise MDMA has shown to help people suffering with PTSD. Put together as a whole, Emerson offers us a destigmatized and inspiring view of MDMA beyond the common street descriptions of Ecstasy and Molly.

From MDMA and the Medical Model, Amy then helps us see the many other use-cases for psychedelics that have a long and varied history. Building on issues of trauma and the importance of spiritually reconnecting with ourselves, we walk through the psychological benefits that can come with right-use of psychedelics.

Finally, this conversation opens the visions of what future of psychedelic use in society through thoughtful contexts that track safety concerns and how, much like meditation, these ‘medicines’ can have a place in our society like Buddhist and meditation practices have entered our culture.

All in all, Breaking the Stigma is a podcast of significance, as it invites us to reconsider our biases around psychedelics at a time when our society is challenged by mental health matters like trauma and the pervasive disconnection from nature and spiritual renewal.

*****

About: Amy Emerson is a highly respected leader in the field of psychedelic-assisted therapy. She was Lykos Therapeutics (formerly MAPS PBC) CEO for an important period in advancing MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD) as a drug with the FDA

She earned a Bachelor of Science in Genetics and Cell Biology from Washington State University and spent the early career involved in roles at pharmaceutical companies, where she contributed to the development of therapies in immunology, oncology, and vaccines .​

In 2003, she began volunteering with the Multidisciplinary Association for Psychedelic Studies (MAPS), assisting with clinical research monitoring. Her expertise was instrumental in establishing MAPS' clinical department and managing the MDMA Clinical Development Program. When MAPS founded its Public Benefit Corporation (MAPS PBC) in 2014 to develop and commercialize MDMA-assisted therapy, Emerson was appointed CEO .​

Under her leadership, the organization, later rebranded as Lykos Therapeutics, completed multiple Phase 2 and Phase 3 clinical trials and raised approximately $150 million in funding. The company grew to over 120 employees, all working toward the goal of obtaining FDA approval for MDMA-assisted therapy for PTSD .​

Amy resigned form her CEO role in September 2024. Currently she is a senior advisor to Lykos and an independent psychedelic research consultant, awaiting the next big adventure.

*****

Chapters

00:00 Introduction and Setting the Stage

02:40 The Evolution of Psychedelic Research

06:10 Understanding Stigma and Its Origins

10:54 MDMA: From Therapy to Recreation

16:33 Therapeutic Applications of MDMA

20:28 Navigating the FDA and Drug Development

24:45 Challenges